

IFNA4


Recombinant Human Interferon alpha-4 (Fc Tag)

Catalog No.	CRH454A-Fc CRH454B-Fc	Quantity:	50 µg 100 µg
Alternate Names:	Interferon alpha-4, IFN-alpha-4, Interferon alpha-4B, Interferon alpha-76, Interferon alpha-M1		
Description:	Interferon, alpha 4 (IFNA4) belongs to the alpha/beta interferon family. Two variants of IFNA4 (IFNA4a and IFNA4b) are known, which differ from each other by changes in their coding regions at nucleotide positions 22 and 41 and can be distinguished by selective restriction enzyme analysis. Interferons are produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation.		
UniProt ID:	P05014		
Accession Number:	NP_066546.1		
Protein Construction:	A DNA sequence encoding the mature form of human IFN-α4a (Cys 23-Asp 189) was expressed with the N-terminal fused Fc region of human IgG1.		
Source:	HEK293 Cells		
Formulation:	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.		
Molecular Weight:	The recombinant human Fc/IFN-α4a is a disulfide-linked homodimeric protein. The reduced monomer consists of 403 amino acids and has a predicted molecular mass of 46 kDa. As a result of glycosylation, the apparent molecular mass of rh Fc/IFN-α4a monomer is approximately 50 kDa in SDS-PAGE under reducing conditions.		
Purity:	> 97 % as determined by SDS-PAGE.		
Endotoxin Level:	< 1.0 EU per µg protein as determined by the LAL method.		
Biological Activity:	Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV). The EC50 for this effect is 0.2-1 ng/mL.		
Predicted N-terminal:	Glu		


Reconstitution: **Centrifuge vial prior to opening.** Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial. **DO NOT VORTEX.** Allow several minutes for complete reconstitution.

Storage & Stability: Stable for up to 1 year from date of receipt at -20°C to -80°C. After reconstitution, store working aliquots at -20°C to -80°C. **Avoid repeated freeze-thaw cycles.**

Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV). The EC₅₀ for this effect is 0.2-1 ng/mL.



SDS-PAGE



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.